insights_auto
Why is MVIR up 3,22%?
Dive Deeperchevron_right
MVIR:STO
Medivir AB
SEKÂ 1,54
arrow_upward
+3,22%(+0,048) 1D
26 Okt., 17:29:39 GMT+1 · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for MVIR...
Open
SEKÂ 1,48
High
SEKÂ 1,55
Low
SEKÂ 1,47
Mkt. cap
959,99Â m
Avg. vol.
1,32Â m
Volume
811,36Â k
52-wk high
SEKÂ 2,88
52-wk low
SEKÂ 0,34
EPS
-SEKÂ 0,37
Shares outstanding
624,18Â m
No. of employees
6
Open
SEKÂ 1,48
High
SEKÂ 1,55
Low
SEKÂ 1,47
Mkt. cap
959,99Â m
Avg. vol.
1,32Â m
Volume
811,36Â k
52-wk high
SEKÂ 2,88
52-wk low
SEKÂ 0,34
EPS
-SEKÂ 0,37
Shares outstanding
624,18Â m
No. of employees
6
News stories
From web sources and news partners
NDTV Profit
·
6 minute gelede
Wall Street Highlights: S&P 500, Nasdaq Gain As Investors Parse Anthropic IPO Filing
TechPowerUp
·
1 uur gelede
Anthropic Files to Go Public on Nasdaq, Reveals $16.3 Billion in First-Half Revenue
Sri Lanka Guardian
·
19 minute gelede
Anthropic files for Nasdaq listing as AI spending concerns unsettle investors
Yahoo Finance
·
4 uur gelede
Charles Payne: Key players are focused on 'building out a prominent place in tomorrow's world'
Profile
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
About Medivir AB